Astera Labs (ALAB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALAB SEC filings page.
Astera Labs (ALAB) reported $1.2B in revenue over the twelve months to Jun 30, 2026, up 98.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Astera Labs turned rapid expansion into profit and cash in FY2025, with low leverage and ample current-asset coverage supporting operations.
The key shift is not merely profitability: FY2024's net loss of$83M coexisted with operating cash flow of$137M , while FY2025's net profit of$219M produced$319M of operating cash flow. That widening alignment suggests earnings quality improved as reported profit became the main source of cash generation.
Operating leverage, not gross-margin expansion, drove the profit inflection. FY2025 gross margin was
The balance sheet is equity-funded and lightly levered. Liabilities of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Astera Labs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Astera Labs held $1.2B in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $319.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Astera Labs scores 86/100 among other emerging companies.
Astera Labs had 170M shares outstanding at the end of fiscal year 2025, against 162M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Astera Labs scores 10/100 among other emerging companies.
Astera Labs spent $304.0M on research and development in fiscal year 2025, which was 44.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Astera Labs scores 74/100 among other emerging companies.
Astera Labs reported revenue of $852.5M in fiscal year 2025, against $396.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Astera Labs scores 90/100 among other emerging companies.
Astera Labs's operations generated $319.3M of cash in fiscal year 2025, against $136.7M generated in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Astera Labs scores 100/100 among other emerging companies.
Astera Labs's cash, cash equivalents and investments came to $1.2B at the end of fiscal year 2025, against $168.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Astera Labs scores 93/100 among other emerging companies.
Astera Labs scores 226.15, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($62.9B) relative to total liabilities ($168.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Astera Labs passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Astera Labs generates $1.46 in operating cash flow ($319.3M OCF vs $219.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Astera Labs generated $392.4M in revenue in Q2 2026. This represents an increase of 104.5% from the same quarter a year earlier. Against the prior quarter it is up 27.3%.
Astera Labs's EBITDA was $93.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 126.2% from the same quarter a year earlier. Against the prior quarter it is up 42.1%.
Astera Labs reported $153.1M in net income in Q2 2026. This represents an increase of 198.9% from the same quarter a year earlier. Against the prior quarter it is up 90.6%.
Astera Labs earned $0.83 per diluted share (EPS) in Q2 2026. This represents an increase of 186.2% from the same quarter a year earlier. Against the prior quarter it is up 88.6%.
Cash & Balance Sheet
Astera Labs generated $67.2M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 49.6% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.
Astera Labs held $111.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Astera Labs's gross margin was 73.3% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.0 percentage points.
Astera Labs's operating margin was 22.7% in Q2 2026, reflecting core business profitability. This is up 2.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.7 percentage points.
Astera Labs's net profit margin was 39.0% in Q2 2026, showing the share of revenue converted to profit. This is up 12.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.0 percentage points.
Astera Labs's ROE was 8.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.
Capital Allocation
Astera Labs invested $135.9M in research and development in Q2 2026. This represents an increase of 103.7% from the same quarter a year earlier. Against the prior quarter it is up 8.2%.
Astera Labs invested $20.5M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 911.8% from the same quarter a year earlier. Against the prior quarter it is up 169.8%.
Not reported for Q2 2026.
ALAB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $392.4M+104.5% | $308.4M+93.4% | $270.6M+91.8% | $230.6M+103.9% | $191.9M+149.7% | $159.4M+144.3% | $141.1M+179.3% | $113.1M+206.2% |
| Cost of Revenue | $104.8M+126.1% | $73.2M+82.9% | $66.1M+80.4% | $54.8M+117.2% | $46.4M+172.8% | $40.0M+171.6% | $36.6M+219.0% | $25.2M+185.7% |
| Gross Profit | $287.6M+97.6% | $235.1M+96.9% | $204.5M+95.8% | $175.8M+100.1% | $145.6M+143.2% | $119.4M+136.4% | $104.4M+167.6% | $87.9M+212.7% |
| R&D Expenses | $135.9M+103.7% | $125.6M+94.6% | $93.8M+65.9% | $78.9M+55.8% | $66.7M+66.4% | $64.6M+20.5% | $56.5M+187.6% | $50.7M+145.6% |
| SG&A Expenses | $36.0M+76.2% | $25.8M+17.9% | $23.6M-5.4% | $22.1M-3.3% | $20.5M-7.2% | $21.9M-10.4% | $25.0M+366.1% | $22.9M+479.0% |
| Operating Income | $89.2M+124.4% | $61.8M+447.9% | $67.0M+46398.6% | $55.4M+722.8% | $39.8M+263.4% | $11.3M+113.6% | $144K-98.4% | -$8.9M-350.0% |
| EBITDA | $93.1M+126.2% | $65.5M+429.1% | $69.8M+5794.2% | $56.9M+802.9% | $41.2M+274.1% | $12.4M+115.0% | $1.2M-87.7% | -$8.1M-413.4% |
| Income Tax | -$50.3M-8875.5% | -$6.9M+31.7% | $33.9M+342.2% | -$24.3M-352.4% | -$560K+91.4% | -$10.1M-180.3% | -$14.0M-285.9% | $9.6M+234.7% |
| Net Income | $153.1M+198.9% | $80.3M+152.4% | $45.0M+82.0% | $91.1M+1300.0% | $51.2M+778.8% | $31.8M+134.2% | $24.7M+72.5% | -$7.6M-143.1% |
| EPS (Basic) | $0.89+187.1% | $0.47+147.4% | $0.27+8.0% | $0.54+1180.0% | $0.31+720.0% | $0.19+110.7% | $0.25-37.5% | -$0.05+37.5% |
| EPS (Diluted) | $0.83+186.2% | $0.44+144.4% | $0.25 | $0.50+1100.0% | $0.29+680.0% | $0.18 | $0.25 | -$0.05 |
| Diluted Shares (Avg) | 183M+2.9% | 181M+1.7% | N/A | 181M+15.2% | 178M+14.8% | 178M | N/A | 157M |
Not reported in any period shown, so not listed: Interest Expense.
ALAB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.9B+51.9% | $1.7B+47.9% | $1.5B+45.3% | $1.4B+42.5% | $1.3B+38.9% | $1.1B+29.7% | $1.1B+437.2% | $983.1M |
| Current Assets | $1.7B+39.9% | $1.4B+31.3% | $1.4B+34.5% | $1.3B+36.4% | $1.2B+32.5% | $1.1B+25.9% | $1.0B+445.2% | $945.6M |
| Cash & Equivalents | $111.5M-31.3% | $148.3M+71.6% | $167.6M+110.7% | $140.4M+11.3% | $162.3M-61.4% | $86.4M-87.6% | $79.6M+76.4% | $126.1M+234.3% |
| Short-Term Investments | $1.1B+26.4% | $1.0B+23.6% | $1.0B+22.3% | $994.0M+30.7% | $902.8M+120.2% | $838.3M+696.0% | $834.8M+701.0% | $760.7M |
| Inventory | $113.8M+94.2% | $60.2M+17.8% | $59.0M+36.5% | $51.7M+111.6% | $58.6M+105.1% | $51.1M+72.7% | $43.2M+79.4% | $24.4M |
| Accounts Receivable | $192.5M+691.5% | $134.8M+93.2% | $83.2M+114.4% | $42.9M+69.0% | $24.3M+9.4% | $69.8M+316.4% | $38.8M+365.6% | $25.4M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $91.6M | $87.7M | $19.0M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $205.8M+51.7% | $165.3M+106.2% | $168.2M+87.5% | $129.5M+38.5% | $135.7M+93.1% | $80.1M+42.8% | $89.7M-69.5% | $93.5M |
| Current Liabilities | $164.3M+54.4% | $125.0M+61.8% | $133.0M+53.7% | $101.0M+14.7% | $106.4M+66.0% | $77.3M+69.5% | $86.5M+146.7% | $88.0M |
| Non-Current Liabilities | $41.5M+41.6% | $40.2M+1310.3% | $35.1M+1009.8% | $28.5M+426.4% | $29.3M+373.5% | $2.9M-72.9% | $3.2M-98.8% | $5.4M |
| Total Equity | $1.7B+51.9% | $1.5B+43.4% | $1.4B+41.3% | $1.3B+43.0% | $1.1B+34.4% | $1.0B+28.8% | $964.8M+1087.5% | $889.6M+862.7% |
| Retained Earnings | $243.7M+293.8% | $90.6M+151.2% | $10.3M+105.0% | -$34.6M+85.2% | -$125.8M+44.3% | -$177.0M+19.0% | -$208.8M-66.5% | -$233.5M |
Not reported in any period shown, so not listed: Long-Term Debt.
ALAB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $87.7M-35.2% | $74.6M+610.2% | $95.3M+139.9% | $78.2M+23.1% | $135.4M+354.1% | $10.5M+187.6% | $39.7M+175.7% | $63.5M+19114.4% |
| Depreciation & Amortization | $3.9M+178.6% | $3.7M+236.4% | $2.8M+172.0% | $1.5M+87.5% | $1.4M+100.0% | $1.1M+79.2% | $1.0M+66.7% | $800K+100.0% |
| Stock-Based Compensation | $64.0M+80.4% | $48.9M+15.2% | N/A | $40.7M-10.5% | $35.5M-17.6% | $42.4M-56.6% | N/A | $45.5M+1579.6% |
| Capital Expenditures | $20.5M+911.8% | $7.6M+67.1% | $18.7M+21.0% | $12.3M-26.4% | $2.0M+52.8% | $4.5M+32.6% | $15.4M+1428.0% | $16.7M+2168.6% |
| Free Cash Flow | $67.2M-49.6% | $67.0M+1023.4% | $76.6M+215.7% | $65.9M+40.7% | $133.3M+368.1% | $6.0M+2516.2% | $24.3M+81.2% | $46.8M+4474.9% |
| Investing Cash Flow | -$131.6M-106.6% | -$94.0M-2286.0% | -$72.8M+20.4% | -$101.0M+71.9% | -$63.7M+78.9% | -$3.9M+7.3% | -$91.4M-1433.0% | -$359.4M-538.8% |
| Financing Cash Flow | $7.0M+48.8% | $82K-78.8% | $3.7M-34.0% | $952K0.0% | $4.7M+302.2% | $386K-99.9% | $5.7M+633.6% | $952K+47.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ALAB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.3%-2.6pp | 76.3%+1.4pp | 75.6%+1.5pp | 76.3%-1.5pp | 75.8%-2.0pp | 74.9%-2.5pp | 74.0%-3.2pp | 77.7%+1.6pp |
| Operating Margin | 22.7%+2.0pp | 20.1%+13.0pp | 24.8%+24.6pp | 24.0%+31.9pp | 20.7%+52.4pp | 7.1% | 0.1%-17.8pp | -7.9%-2.5pp |
| Net Margin | 39.0%+12.3pp | 26.0%+6.1pp | 16.6%-0.9pp | 39.5%+46.2pp | 26.7%+36.5pp | 20.0% | 17.5%-10.8pp | -6.7%+1.7pp |
| Return on Equity | 8.9%+4.4pp | 5.4%+2.3pp | 3.3%+0.7pp | 7.2%+8.0pp | 4.5%+5.4pp | 3.0%+14.6pp | 2.6% | -0.9% |
| Return on Assets | 7.9%+3.9pp | 4.8%+2.0pp | 2.9%+0.6pp | 6.5%+7.3pp | 4.0%+4.9pp | 2.8%+13.6pp | 2.3%-5.0pp | -0.8% |
| Current Ratio | 10.05-1.0x | 11.30-2.6x | 10.24-1.5x | 12.78+2.0x | 11.10-2.8x | 13.92-4.8x | 11.71+6.4x | 10.74 |
| Debt-to-Equity | 0.120.0x | 0.110.0x | 0.120.0x | 0.100.0x | 0.120.0x | 0.080.0x | 0.09 | 0.10 |
| Asset Turnover | 0.20+0.1x | 0.190.0x | 0.180.0x | 0.160.0x | 0.15+0.1x | 0.14+0.1x | 0.13-0.1x | 0.12 |
| FCF Margin | 17.1%-52.3pp | 21.7%+18.0pp | 28.3%+11.1pp | 28.6%-12.8pp | 69.5%+32.4pp | 3.7%+3.4pp | 17.2%-9.3pp | 41.4%+44.3pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Astera Labs ALAB | FY2025 | $852.5M | $219.1M | 25.7% | $62.9B | 76/100 |
| Monolithic Power Systems, Inc. MPWR | FY2025 | $2.8B | $621.5M | 22.3% | $72.7B | 88/100 |
| Microchip Technology Inc MCHP | FY2026 | $4.7B | $230.0M | 4.9% | $44.2B | 48/100 |
| Credo Technology Group CRDO | FY2026 | $1.3B | $472.3M | 35.4% | $39.9B | 78/100 |
| NXP Semiconductors N.V. NXPI | FY2025 | $12.3B | $2.0B | 16.5% | $61.0B | 62/100 |
| Marvell Technology, Inc. MRVL | FY2026 | $8.2B | $2.7B | 32.6% | $243.8B | 56/100 |
Where Astera Labs Ranks
Frequently Asked Questions
What is Astera Labs's annual revenue?
Astera Labs (ALAB) reported $852.5M in total revenue for fiscal year 2025. This represents a 115.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Astera Labs's revenue growing?
Astera Labs (ALAB) revenue grew by 115.1% year-over-year, from $396.3M to $852.5M in fiscal year 2025.
Is Astera Labs profitable?
Yes, Astera Labs (ALAB) reported a net income of $219.1M in fiscal year 2025, with a net profit margin of 25.7%.
What is Astera Labs's EBITDA?
Astera Labs (ALAB) had EBITDA of $180.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Astera Labs's gross margin?
Astera Labs (ALAB) had a gross margin of 75.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Astera Labs's operating margin?
Astera Labs (ALAB) had an operating margin of 20.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Astera Labs's net profit margin?
Astera Labs (ALAB) had a net profit margin of 25.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Astera Labs's return on equity (ROE)?
Astera Labs (ALAB) has a return on equity of 16.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Astera Labs's free cash flow?
Astera Labs (ALAB) generated $281.8M in free cash flow during fiscal year 2025. This represents a 175.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Astera Labs's operating cash flow?
Astera Labs (ALAB) generated $319.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Astera Labs's total assets?
Astera Labs (ALAB) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Astera Labs's capital expenditures?
Astera Labs (ALAB) invested $37.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Astera Labs spend on research and development?
Astera Labs (ALAB) invested $304.0M in research and development during fiscal year 2025.
What is Astera Labs's current ratio?
Astera Labs (ALAB) had a current ratio of 10.24 as of fiscal year 2025, which is generally considered healthy.
What is Astera Labs's debt-to-equity ratio?
Astera Labs (ALAB) had a debt-to-equity ratio of 0.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Astera Labs's return on assets (ROA)?
Astera Labs (ALAB) had a return on assets of 14.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Astera Labs's P/E ratio?
Astera Labs (ALAB) trades at 170x earnings, its market capitalization divided by net income of $369.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $62.9B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Astera Labs's price-to-sales ratio?
Astera Labs (ALAB) trades at 52.3x sales, its market capitalization divided by revenue of $1.2B revenue, trailing 12 months to June 30, 2026. The market capitalization is $62.9B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Astera Labs's Altman Z-Score?
Astera Labs (ALAB) has an Altman Z-Score of 226.15, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Astera Labs's Piotroski F-Score?
Astera Labs (ALAB) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Astera Labs's earnings high quality?
Astera Labs (ALAB) has an earnings quality ratio of 1.46x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Astera Labs?
Astera Labs (ALAB) scores 76 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.